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Inﬂammatory maturation of M1 macrophages by proinﬂammatory stimuli such as toll like receptor li-
gands results in profound metabolic reprogramming resulting in commitment to aerobic glycolysis as
evidenced by repression of mitochondrial oxidative phosphorylation (OXPHOS) and enhanced glucose
utilization. In contrast, “alternatively activated” macrophages adopt a metabolic program dominated by
fatty acid-fueled OXPHOS. Despite the known importance of these developmental stages on the quali-
tative aspects of an inﬂammatory response, relatively little is know regarding the regulation of these
metabolic adjustments. Here we provide evidence that the immunosuppressive cytokine IL-10 deﬁnes a
metabolic regulatory loop. Our data show for the ﬁrst time that lipopolysaccharide (LPS)-induced gly-
colytic ﬂux controls IL-10-production via regulation of mammalian target of rapamycin (mTOR) and that
autocrine IL-10 in turn regulates macrophage nitric oxide (NO) production. Genetic and pharmacological
manipulation of IL-10 and nitric oxide (NO) establish that metabolically regulated autocrine IL-10 con-
trols glycolytic commitment by limiting NO-mediated suppression of OXPHOS. Together these data
support a model where autocine IL-10 production is controlled by glycolytic ﬂux in turn regulating
glycolytic commitment by preserving OXPHOS via suppression of NO. We propose that this IL-10-driven
metabolic rheostat maintains metabolic equilibrium during M1 macrophage differentiation and that
perturbation of this regulatory loop, either directly by exogenous cellular sources of IL-10 or indirectly via
limitations in glucose availability, skews the cellular metabolic program altering the balance between
inﬂammatory and immunosuppressive phenotypes.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Macrophages are an integral part of the innate immune system;
critical in the maintenance of tissue homeostasis in the healthy
state and instrumental in orchestrating inﬂammatory responses
during disease [1]. Tissue macrophages at homeostasis or those
exposed to cytokines associated with Th2- responses (e.g. IL-4/13)
are considered anti-inﬂammatory. These cells, termed “M2 or “al-
ternatively activated”, produce the cytokine interleukin-10 and are
characterized via enhanced expression of arginase-1, andn open access article under the CC
ral Research Program of the
e Welcome Trust, UK.
views or policies of the De-
ention of trade names, com-
t by the U.S. Government.
icar).scavenger receptors such as SR-A and MARCO. In contrast, “clas-
sically activated” or “M1” macrophages are the result of bacterial/
toll-like receptor (TLR) engagement in conjunction with cytokines
associated with a Th1-like response (e.g. Interferon gamma). These
cells are highly inﬂammatory, producing pro-inﬂammatory cyto-
kines such as IL-12 and tumor necrosis factor (TNF), as well as
inﬂammatory intermediates including eicosanoids, reactive oxy-
gen and nitrogen species [2]. Consistent with their role in the
regulation of inﬂammatory responses, skewing the development,
expansion or perseverance of macrophages through genetic or
biochemical means can result in profound effects for diseases in-
cluding rheumatoid arthritis.
Regardless of their activation status, macrophages must bal-
ance their metabolic demands for energy with the needs of bio-
synthetic pathways necessary for a particular functional proﬁle.
For example, classically activated inﬂammatory macrophages must
simultaneously produce abundant inﬂammatory cytokines andBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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oxidative burst needed for pathogen killing. In addition, they
generate the energy needed for cell adhesion and motility, and the
anabolic intermediates used in the nucleotide synthesis necessary
for enhanced gene expression and proliferation [3]. Lastly, recent
evidence suggests that in dendritic cells, mitochondrial citrate
export during stimulation supports production of cytosolic acetyl-
CoA critical for lipid synthesis that facilities expansion of Golgi and
endoplasmic reticulum needed for effective production of in-
ﬂammatory cytokines. Only when each of these demands is met
can a macrophage effectively carry out its function.
To satiate immediate metabolic demands it would seem in-
tuitive for activated leukocytes to utilize aerobic glycolysis, a quick
but inefﬁcient mechanism for producing ATP. Indeed, recent lit-
erature has suggested that both macrophages and dendritic cells
(DC) undergo a metabolic shift away from mitochondrial oxidative
phosphorylation (OXPHOS) towards aerobic glycolysis when sti-
mulated with the gram-negative bacterial component lipopoly-
saccharide (LPS), a process that has been termed “glycolytic com-
mitment” [4,5]. The profound shift in metabolism permits leuko-
cytes to generate the requisite energy for functionality while
producing the glycolytic intermediates necessary for the pentose
phosphate pathway (PPP) critical for growth and maintenance of
redox potential. As a result, “classically activated” M1 macrophages
that are pro-inﬂammatory are largely dependent on aerobic gly-
colysis and exhibit low levels of mitochondrial respiration [4,6].
Conversely, macrophages “alternatively activated” with IL-4 are not
glycolytically committed and instead utilize mitochondrial fatty
acid oxidation (FAO) for energy production [7,8].
Though commitment to aerobic glycolysis upon leukocyte ac-
tivation has been well documented, the mechanisms associated
with the metabolic reprogramming of macrophages remain poorly
deﬁned. Tannahill et al. recently suggested that macrophage gly-
colytic commitment is, in part, due to an LPS-induced “pseudo
hypoxic “ state in which high succinate promotes stabilization of
HIF-1α, resulting in enhanced glycolysis via expression of glyco-
lytic genes [4]. In parallel, HIF-1α promotes expression of pyruvate
dehydrogenase kinase 1, an inhibitor of pyruvate dehydrogenase,
effectively blocking acetyl-CoA entry into the tricarboxylic acid
(TCA) cycle [9,10]. In contrast, Everts et al. has implicated nitric
oxide (NO) production in LPS-stimulated DC as the driving force in
OXPHOS repression via direct inhibition of the mitochondrial
electron transport chain (ETC). It remains unknown if this me-
chanism plays a role in macrophage metabolism [11].
Interleukin-10 is a potent immunoregulatory cytokine due to
its ability to suppress inﬂammatory responses and induce devel-
opment of T regulatory cells. In the metabolic context, TLR-direc-
ted DC glycolytic reprogramming and subsequent inﬂammatory
responses are blunted via addition of IL-10 [12]. In contrast to DC,
stimulated macrophages are capable of producing relatively high
levels of IL-10 suggesting this cytokine might participate in auto-
crine and paracrine control of metabolic programing. Using bio-
chemical approaches, gene targeted mice, and metabolic ﬂux
analysis, and unbiased metabolomics analysis, here we show that
LPS-driven IL-10 production functions as a metabolic rheostat in
macrophages, permitting these cells to maintain metabolic
equilibrium.2. Materials and methods
2.1. Reagents and antibodies
DETA/NO, PAM3CSK4, LPS (Escherichia coli 0111:B4), 2-Deoxy-D-
glucose (2-DG), oligomycin, rotenone and the mTOR inhibitor
Rapamycin were from Sigma-Aldrich (St. Louis, MO). 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG)
was purchased through Life Technologies (Grand Island, NY). Wes-
tern blotting antibodies anti-AMPKα (#2603) and anti-phospho-
AMPKα (phospho Thr172) (#2535) were from Cell Signaling Tech-
nology (Beverley, MA). Anti-phospho-mTOR (phospho S2481)
(#ab137133) antibody was from Abcam (Cambridge, MA). Anti-Ac-
tin (MAB1501) antibody was from Chemicon International (Teme-
cula, CA). Human and mouse Enzyme-Linked Immunosorbent Assay
(ELISA, IL-10 and TNFα) kits were purchased through eBioscience
(San Diego, CA) and experimentation was performed per manu-
facturer's protocol.
2.2. Mice
Il10/ , and C57BL/6 control mice were maintained and bred in
the Frederick National Laboratory Core Breeding Facility. Animal
care was provided in accordance with the procedures in, “A Guide
for the Care and Use of Laboratory Animals”. Ethical approval for the
animal experiments detailed in this manuscript was received from
the Institutional Animal Care and Use Committee (Permit Number:
000386) at the NCI-Frederick.
2.3. Macrophage culture, stimulation, and immunoblotting
Mouse bone marrow derived macrophages (BMDM) [13] and
human monocyte-derived macrophages (MDM) [14] were isolated
and cultured as previously described. After growing BMDM or
human MDM for 6 days in culture, cells were placed in complete
culture media and pretreated with 2 or 5 mM 2-deoxyglucose (2-
DG) or 100 nm rapamycin for 30 min as indicated prior to addition
of 100 ng/mL of LPS for 4–24 h. For glucose deprivation studies,
cultured BMDM were incubated in culture media containing de-
creasing glucose for 30 min prior to addition of 100 ng/mL of LPS
for 4 h. Protein expression in stimulated macrophages was de-
termined by western blot as previously described [15]. Due to the
protein size similarities, AMPK and pAMPK were analyzed on
parallel blots.
2.4. Metabolic analyses
Oxygen consumption rate (OCR) and extracellular acidiﬁcation
rate (ECAR) were examined using the XF24 Seahorse Metabolic
Analyzer from Seahorse Biosciences. Brieﬂy, cultured BMDM were
plated at a seeding density of 3105 cells/well in 500 μl of com-
plete media. Where noted, data are represented as percent of
control levels calculated as the mean of the third set of ﬂux
readings. All additional values for a given sample are reported
relative to this. Metabolic mitochondrial stress tests were per-
formed via manufacturer's protocol. Mitochondrial OCR is deﬁned
as the percentage of OCR that is oligomycin sensitive. OCR/ECAR
ratios were calculated using the ﬁrst nine determinations of basal
OCR and basal ECAR where indicated. When indicated, 100 ng/mL
LPS, 10 mM 2-DG, and/or 1 μM DETA/NO was added during the
assay to assess metabolic changes. In other assays, BMDM were
incubated in complete culture media supplemented with
100 ng/mL of LPS overnight. Total cellular ATP was assessed using
The ATP Determination Kit (Invitrogen) as per the manufacturer's
directions. Glucose uptake was assayed in BMDM using ﬂuorescent
glucose analog 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-
2-Deoxyglucose (2-NBDG) per manufacturer's protocol. Fluor-
escent uptake was analyzed using LSRFortessa ﬂow cytometer (BD
Biosciences). Data were analyzed using Flowjo software. NO ac-
tivity was assessed via the Greiss Reagent System (Promega),
which measures nitrite concentrations.
Fig. 1. Acute LPS stimulation of human and mouse macrophages leads to an immediate glycolytic burst that is dependent on glucose. Real time OCR and ECAR percent
changes in mouse BMDM 75 mM 2-DG and 100 ng/mL LPS or a combination of both (a). Human MDM real time OCR and ECAR stimulated 710 mM 2-DG, 100 ng/mL of LPS
or a combination of both (b). Data represent percent of resting control levels and are from one experiment representative of 2 (b) or 3 (a) independent experiments
(mean7standard error of the mean (SEM) of the ﬁnal three time points, n¼5 per group). Values for bar graphs are derived from the three data points following addition of
the experimental agent as noted on the line graphs. *p o0.05. Statistical signiﬁcance was assessed by ANOVA with a Bonferroni post-test.
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Fig. 2. Prolonged stimulation of macrophages with LPS leads to glycolytic commitment. OCR, ECAR and OCR/ECAR ratio of mouse BMDM 24 h after LPS administration
(100 ng/mL) (a–c). mRNA levels of glycolytic enzymes HK2, LDHA, and PFK1 were evaluated 24 h after LPS administration to BMDM in which the dotted line indicates control
levels (d). Glucose uptake in LPS treated macrophages (24 h) was assessed by ﬂuorescent 2-NBDG (100 μM) uptake via ﬂow cytometry (e). OCR/ECAR ratio was evaluated in
human MDM 24 h after exposure to 100 ng/mL LPS (f). Metabolic data (a–c, f) are from one experiment representative of at least 3 independent experiments (mean7SEM
n¼5). mRNA analysis (d) is a combination of 2 independent experiments (N¼5). 2-NBDG analysis (e) is a combination of 3 independent experiments *p o0.05. Statistical
signiﬁcance was assessed by Student's t test.
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Wild type (WT) and Il10 / BMDM (10 million cells) were
treated with vehicle (PBS) or 100 ng/mL of LPS for 24 h. Cells were
then washed, gently scraped, pelleted, snap frozen in liquid ni-
trogen and sent to West Coast Metabolomic Center at the Uni-
versity of California, Davis for metabolomic analyses. Brieﬂy,
samples were extracted by 1 mL of degassed acetonitrile, iso-
propanol and water in proportions 3:3:2 at –20 °C, centrifuged and
decanted to complete dryness. A clean-up step with acetonitrile/
water (1:1) removes membrane lipids and triglycerides. The
cleaned extract is aliquoted into two equal portions and the su-
pernatant is dried down again. Internal standards C08-C30 FAMEs
are added and the sample is derivatized by methoxyamine hy-
drochloride in pyridine and subsequently by N-methyl-N-tri-
methylsilyltriﬂuoroacetamide for trimethylsilylation of acidic
protons. Gas Chromatography-Time of Flight analysis was per-
formed by Agilent GC6890/LECO Pegasus III MS.
2.6. Statistical analysis
Data are presented as means 7standard error of mean
(7SEM) and are representative of at least 2 independent experi-
ments. One-way ANOVA followed by Bonferroni’s post was used
for statistical analysis when multiple groups were analyzed. Stu-
dent t test or Mann-Whitney test were used for statistical analysis
when two groups were analyzed. Statistical signiﬁcance was set at
*po0.05.3. Results
3.1. Resting macrophages utilize distinct metabolites to fuel OXPHOS
and aerobic glycolysis
Macrophages have the ability to metabolize glucose, fatty acids,
and glutamine to fuel both aerobic glycolysis and OXPHOS [3].
Consistent with previous literature, we found BMDM to have
substantial oxygen consumption rates (OCR) and low extracellular
acidiﬁcation rates (ECAR) resulting in substantial OCR/ECAR ratios
(Fig S1A). Further, BMDM OCR was fueled predominantly via fatty
acid oxidation (FAO) and ECAR fueled via glucose (Fig S1B and E).
Interestingly, oligomycin caused a suppression of OCR and a re-
active increase in ECAR, possibly in an effort to maintain metabolic
homeostasis (Fig S1). Together these results demonstrate that
resting BMDM are plastic metabolically but preferentially generate
ATP via the utilization of FAO.
3.2. LPS stimulated mouse BMDM and human macrophages undergo
glycolytic reprogramming
Having established the basal metabolic status of macrophages
we next analyzed metabolic responses of BMDM to LPS. LPS sti-
mulation resulted in a progressive increase in ECARs within min-
utes (Fig. 1A). OCRs were unaffected over this timeframe (Fig. 1A).
As shown in Fig. 1, addition of 2-DG during bioenergetic mon-
itoring leads to an instant repression of basal ECARs. Further, 2-DG
severely blunts LPS-stimulated increases in ECAR indicating glu-
cose is absolutely necessary for the acute glycolytic elevation in
BMDM. Identical results were found using human monocyte-de-
rived macrophages (MDM) stimulated with LPS in the presence or
absence of 2-DG (Fig. 1B). Together these data conﬁrm that 2-DG
inhibits the immediate LPS-induced increase in glycolytic ﬂux.
In contrast, prolonged stimulation (24 h) of BMDM with LPS
leads to a glycolytic phenotype characterized by enhancement of
ECAR in combination with signiﬁcant reductions to OCR (Fig. 2Aand B). Best quantitated by a decline in OCR/ECAR ratios; this state
has been termed “glycolytic commitment” in inﬂammatory DC [11]
(Fig. 2C). Notably, the reduction in OXPHOS due to LPS affects both
basal OCR levels as well as spare respiratory capacity indicating a
global suppression of OXPHOS. As expected, glycolytic commit-
ment was associated with transcriptional metabolic reprogram-
ming. BMDM stimulated with LPS for 24 h display signiﬁcant in-
creases to multiple glycolytic genes including hexokinase-2 (Hk2),
lactate dehydrogenase A (Ldha) and phosphofructokinase 1 (Pfk1)
(Fig. 2D). LPS-treated BMDM import 50% more glucose than
unstimulated controls as measured with the ﬂuorescent glucose
analog 2-NBDG (Fig. 2E). Notably, as shown in Fig. 2F, human MDM
also undergo a strong glycolytic commitment as evidenced by a
reduction in OCR/ECAR ratios after overnight culture with LPS.
Taken together, these results show that endotoxin stimulated
BMDM undergo an immediate increase in aerobic glycolysis fol-
lowed by a sustained glycolytic commitment associated with
transcriptional modiﬁcation of metabolic genes.
3.3. Inhibition of LPS-driven glycolysis reduces IL-10 production
Given that macrophages preferentially utilize glycolysis upon
endotoxin stimulation, we sought to determine the ramiﬁcations
of interference of LPS-induced glycolysis via blockade of glucose
utilization with 2-DG might have on inﬂammatory outcome. We
assayed levels of the LPS-inducible cytokines TNFα and IL-10. In-
terestingly, quantitative RT-PCR analyses revealed a substantial
reduction in Il10 mRNA and a modest increase in Tnfa when
BMDM were pretreated with 2-DG 30 min prior to a 4 h stimula-
tion with LPS (Fig. 3A and B). 2-DG suppression of IL-10 production
was conﬁrmed by assaying secreted IL-10, with no signiﬁcant
change in secreted TNFα (Fig. 3C and D). To ensure these results
were not off-target effects of 2-DG, BMDM were stimulated with
LPS in decreasing amounts of glucose. BMDM stimulated in media
with less than 0.5 mM glucose produced less IL-10 than those
cultured in higher levels with no signiﬁcant change in TNFα
(Fig. 3E and F). Additionally, human MDM cultured under identical
conditions mirrored the preferential reduction of IL-10 with 2-DG
pre-stimulation (Fig. 3G and H). Together these data show that
LPS-induced IL-10 production is sensitive to the availability of
glucose in macrophages.
3.4. IL-10 production is regulated via AMPK sensing of cellular ATP
levels
Mammalian target of rapamycin (mTOR) is a mediator of IL-10
production in macrophages, and is in turn regulated by AMP ki-
nase (AMPK). AMPK is a metabolic sensor that detects elevations
in ATP/AMP ratios within the cell and initiates programs to in-
crease ATP production [16]. Therefore, we hypothesized that glu-
cose deprivation of glycolytically committed macrophages might
result in reductions in cellular ATP levels, activation of AMPK, re-
pression of mTOR and reduced IL-10 production. To test this pos-
sibility, we stimulated macrophages with LPS in the presence or
absence of 2-DG and assayed cellular ATP (Fig. 4A). In addition, we
stimulated cells with LPS and 2-DG before western blotting to
detect the levels of phosphorylated AMPK (pAMPK) and phos-
phorylated mTOR (pMTOR) (Fig. 4B). BMDM stimulated with LPS
had lower levels of ATP but these levels were not sufﬁcient to elicit
the activation of AMPK. Rather, in LPS stimulated macrophages
levels of pAMPK fell and mTORC activation proceeded unabated
(Fig. 4B). In contrast, incubation of macrophages with 2-DG or
2-DG followed by LPS administration reduced ATP levels to lower
than LPS treatment alone (Fig. 4A). Accordingly, BMDM treated
with 2-DG or 2-DG and LPS now showed enhanced pAMPK and
concomitant repression of mTOR activation consistent with
Fig. 3. Inhibition of glycolysis in LPS treated macrophages leads to a reduction in IL-10 but not TNFα. IL-10 and TNFα mRNA (a, b) and protein content (c, d) was
measured in BMDM 7pretreatment of 2-DG (2 mM, 5 mM) followed by stimulation of LPS (100 ng/mL) for 4–5 h. IL-10 and TNFα (e, f) protein content was measured in LPS
(100 ng/mL) stimulated BMDM incubated in titrating amount of glucose for 5 h. Human MDM IL-10 and TNFα (g, h) protein content was assessed 5 h post LPS and/or 2-DG
pre-treatment. Data are a combination of 3 (a, b) independent experiments or a representative of at least 2 (e, f) or 3 (c, d, g, h) independent experiments *po0.05. Statistical
signiﬁcance was assessed by ANOVA with a Bonferroni post-test. Error bars represent 7SEM.
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Fig. 4. LPS stimulated IL-10 production in macrophages is controlled via ATP abundance, which acts through AMPK activation and mTOR inhibition. ATP content was
measured in BMDM7pretreatment of 2-DG (5 mM) for 30 min followed by stimulation of LPS (100 ng/mL) for 4 h (a). BMDM were pretreated with 2-DG 7LPS and
immunoblotted for AMPK, pAMPK, pMTOR, and β-actin (b). IL-10 and TNFα mRNA (c, d) and protein content (e, f) was measured in BMDM 7pretreatment of Rapamycin
(100 nM) followed by stimulation of LPS (100 ng/mL) for 4–5 h. Data are a combination of at least 3 (a, c-d) independent experiments or a representative ﬁgure of at least
3 independent experiments (b, e-f) *po0.05. Statistical signiﬁcance was assessed by ANOVA with a Bonferroni post-test. Error bars represent 7SEM.
W.A. Baseler et al. / Redox Biology 10 (2016) 12–2318reductions in IL-10 production (Fig. 4B). Consistent with this me-
chanism we found that similar to 2-DG, rapamycin potently sup-
pressed LPS-induced IL-10 at mRNA and protein levels without
affecting TNFα, conﬁrming mTOR signaling as a key component in
LPS-induced IL-10 production (Fig. 4C-F). Taken together, these
results suggest a model where LPS stimulation leads to transient
reductions in ATP that are not sufﬁcient to activate AMPK allowing
mTOR activation to proceed and IL-10 production to occur. How-
ever, in the presence of 2-DG, glycolysis is suppressed and ATP
levels fall sufﬁciency low to activate AMPK, suppressing mTOR and
blocking IL-10 production.
3.5. Autocrine IL-10 controls both glycolysis and OXPHOS in
macrophages
Previous literature has suggested that exogenous IL-10 is cap-
able of repressing LPS-driven glycolysis and inﬂammatory function
in DC [12]. Thus, we hypothesized that because LPS-stimulated
macrophages are a substantial source of IL-10, and that IL-10 is
regulated by the rate of glycolysis, this cytokine may act in anautocrine fashion as a rheostat tempering glycolytic commitment.
If endogenous LPS-induced IL-10 production is a regulator of me-
tabolic programing, BMDM lacking IL-10 should exhibit a greater
degree of metabolic commitment. To test this possibility, we
generated BMDM from mice lacking Il10. ECAR rates of Il10 /
BMDM stimulated with LPS overnight were signiﬁcantly higher
when compared to LPS stimulated wild type (WT) BMDM con-
ﬁrming that autocrine IL-10 production participates in glycolytic
regulation (Fig. 5A). Furthermore, OCRs of Il10 / BMDM stimu-
lated overnight with LPS were signiﬁcantly repressed when com-
pared to LPS stimulated WT BMDM suggesting that autocrine IL-10
might regulate both arms of glycolytic commitment (Fig. 5B). Ac-
cordingly, the OCR/ECAR ratio of Il10/ BMDM stimulated over-
night with LPS was signiﬁcantly reduced compared to LPS stimu-
lated WT BMDM indicating an enhanced glycolytic commitment in
Il10/ BMDM (Fig. 5C).
The mechanism for OCR suppression in LPS-stimulated mac-
rophages remains unclear. Everts et al. have shown endogenous
NO is responsible for the suppression of OCR in DC [11]. Therefore,
we stimulated BMDM under conditions we anticipated would
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Fig. 5. IL-10 control of macrophage metabolism is via regulation of NO. Metabolic analyses were performed on WT and Il10-/- BMDM 24 h after LPS (100 ng/mL)
stimulation including ECAR fold change of LPS treated BMDM compared to non-LPS treated BMDM (a), percent mitochondrial OCR (b), and OCR/ECAR ratio (c). BMDM were
treated with for 24 h 7 IFNγ (50 ng/mL), 7LPS (100 ng/mL), 7Pam3Csk4 (100 ng/mL) in which nitrite concentrations (d) and OCR (e) were measured. Percent mi-
tochondrial OCR was measured after the addition of NO donor DETA/NO (1 mM) (f). WT and Nos2-/- BMDM mitochondrial OCR were measured after 24 h treatment of
IFNγ7LPS (g). Nitrite concentrations were evaluated in WT and IL-10/ BMDM 24 h post treatment 7 IL-10 (50 ng/mL), 7LPS (h). Metabolic data (a–c, e–g) are re-
presentative of 2 independent experiments (mean7SEM, n¼5) *po0.05. Figs. d and h are representative ﬁgures from 3 independent experiments *po0.05. Statistical
signiﬁcance for a–d, f–h were assessed by Student's t test. Statistical signiﬁcance for e and g were assessed by ANOVAwith a Bonferroni post-test. Error bars represent 7SEM.
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Fig. 6. Primary metabolomic analyses reveal broad scale alterations to glycolytic and TCA cycle metabolites in Il10 / M1 macrophages. WT and Il10/ BMDM were
incubated for 24 h in 100 ng/mL LPS prior to GC-TOF analyses. Schematics shown summarize the fold change differences when comparing LPS stimulated Il10/ vs LPS
stimulated WT macrophages (a). Colors indicate upregulation (red), downregulation (blue), unchanged (black), or undeﬁned (grey) metabolites. All red or blue colors are
statistically signiﬁcant (p-valueo0.05 and fold change 410%) except for glucose 6-phosphate (p-valueo0.055, a). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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W.A. Baseler et al. / Redox Biology 10 (2016) 12–23 21yield various levels of NO production and assayed OXPHOS. As
shown in Fig. 5d, stimulation with LPS under conditions that drive
glycolytic commitment (Fig. 2) elicited substantial nitrite accu-
mulation in the media, indicative of NO production. In contrast,
stimulation with the TLR1/2 agonist Pam3CSK4 failed to induce NO
production. Co-stimulation with interferon gamma (IFNγ) pro-
moted large amounts of nitrite production in combination with
either LPS or Pam3CSK4. Therefore, we tested the effects of
Pam3CSK4 and IFNγ on macrophage OCR. Consistent with the ni-
trite induction, Pam3CSK4 failed to suppress macrophage OCR
unless it was combined with IFNγ (Fig. 5E). These data suggest that
Toll receptor-mediated glycolytic commitment is dependent on
the production of NO.
To directly test the effects of NO on macrophage OXPHOS we
tested the effects of direct application of NO. Concentrations of the
NO donor DETA/NO that provide concentrations of NO similar to
those obtained by LPS and IFNγ-stimulated macrophages led to
signiﬁcant repression of OXPHOS in BMDM (Fig. 5F). Conversely,
after culture in LPS, BMDM from Nos2/ mice had signiﬁcantly
higher OCRs than WT cells indicating NO is necessary and sufﬁ-
cient for OXPHOS repression in macrophages (Fig. 5G). Based on
these data, we hypothesized that modulation of IL-10 would alter
levels of NO in LPS-treated BMDM explaining the effects of en-
dogenous IL-10 on OXPHOS. Indeed, LPS-stimulated BMDM in-
cubated with IL-10 overnight displayed decreased NO production
when compared with LPS stimulation alone (Fig. 5H). Conversely,
NO levels were signiﬁcantly higher in LPS treated Il10 / BMDM
(Fig. 5H). These data indicate that autocrine IL-10 regulates LPS-
induced NO production in BMDM, which in turn is capable of
controlling OXPHOS.
Recently, broad scale metabolomic studies on LPS-treated
BMDM have shed light on metabolite ﬂuxuations that underlies
the phenotypic manifestations associated with glycolytic com-
mitment [4]. Indeed, we also show global metabolic shifts in LPS-
treated BMDM including upregulation of glycolytic metabolites (6/
7 assayed) (Fig S2). In addition, LPS-treated BMDM have higher
citrate, cis-aconitate and itaconic acid levels; known markers of
M1 macrophage polarization [17]. Because our data suggest that
both IL-10 and NO play major roles in glycolytic commitment of
M1 macrophages, we performed unbiased metabolomic studies on
WT, and Il10 / BMDM cultured with or without LPS for 24 h
(Fig. 6). In agreement with our metabolic ﬂux data, LPS stimulated
Il10 / BMDM had elevated levels of glycolytic metabolites (4/7
assayed) and more pronounced suppression of TCA metabolites (5/
6 assayed) when compared to LPS treated WT BMDM (Fig. 6).
Notably, the LPS-induced increase in succinate in WT cells was
abolished in macrophages lacking IL-10 yet the reductions of al-
pha-ketogluterate, indicative of the LPS-induced “TCA break”, is
completely intact. This suggests the effects of IL-10 on metabolism
are downstream of the break and that they may impact Hif-1α
activation by restraining succinate levels. LPS treated Il10 /
BMDM also had decreased pyruvate and lactate levels consistent
with their enhanced Ldha expression (Fig. 2D), and elevated ECAR
(Fig. 6).
As might be expected, we found that LPS treated BMDM ac-
cumulate citrulline as a result of the conversion of arginine during
the production of NO. Consistent with the high production of NO
in macrophages lacking IL-10 these cells had high citrulline levels
and were depleted of ornithine, an alternative destination for ar-
ginine. Similarly, proline levels declined in stimulated Il10 /
macrophages and overall levels of putrescine were lower in these
cells consistent with depletion of cellular arginine levels. Taken
together these data highlight the substantial effects of IL-10 on M1
metabolic programing.4. Discussion
Macrophages are immune sentinels that serve as a critical ﬁrst
line of defense during infection [1]. In recent years, it has been
shown that stimulation of leukocytes leads to profound metabolic
changes that have the ability to alter cellular activation, differ-
entiation, proliferation, and immune functionality [3,18]. During
M1 polarization, prolonged LPS stimulation elicits a metabolic
commitment towards aerobic glycolysis with strong counter in-
hibition of mitochondrial OXPHOS [4,6]. Though this metabolic
phenomenon has been documented within macrophages, the
underlying mechanisms associated with the regulation of glyco-
lytic commitment during polarization remain poorly deﬁned.
IL-10 is highly regulated in macrophages. Co-stimulation of
macrophages with immune complexes induces IL-10 via a me-
chanism involving the re-conﬁguration of the Il10 locus in a
MAPK-dependent manner [19]. Similarly, co-engagement of the
immunosuppressive receptor, triggering receptor expressed on
myeloid cells- (TREM)-2, promotes IL-10 secretion [15]. Ligands
that elicit strong phosphoinositide-3 kinase (PI3K) activation are
associated with IL-10 production and via this pathway mTOR has
been revealed as key regulator [20–22]. Our ﬁndings are consistent
with mTOR-driven IL-10 as we ﬁnd that 2-DG induced ATP star-
vation enhanced phospho-AMP Kinase, inhibited mTOR and re-
duced IL-10 production. Accordingly, it has been shown that LPS
stimulation of DC leads initially to suppression pAMPK. We believe
this also occurs in macrophages, facilitating a burst in IL-10 pro-
duction, likely through a mechanism involving mTOR activation
[12]. Our data show, however, that the very low ATP levels re-
sulting from disruption of glycolysis overwhelm the LPS-driven
suppression of pAMPK, leading to diminished IL-10 production. In
addition, this ﬁnding suggests that although resting macrophages
have substantial levels of OXPHOS they are heavily dependent on
glycolytic ﬂux to maintain cellular energy levels.
The persistence of substantial OXPHOS over the ﬁrst several
hours of LPS stimulation, in conjunction with the profound sup-
pression seen after 24 h of polarization, suggested that in macro-
phages repression of OXPHOS might be transcriptional. NO is a
known inhibitor of the mitochondrial ETC via reversible inhibition
of cytochrome c oxidase and the covalent modiﬁcation of thiols in
Complex I [23,24]. NO is strongly induced during LPS stimulation
and we ﬁnd it to be both necessary and sufﬁcient for the OXPHOS
repression evident in M1 macrophages. M1 macrophages derived
from mice lacking Nos2 do not display reduced OXPHOS. In addi-
tion, direct application of an NO donor potently suppresses mac-
rophage OXPHOS. Although our ﬁnding that NO is responsible for
the suppression of OXPHOS associated with glycolytic commit-
ment of macrophages is consistent with reports in DC, it is in-
congruent with previous studies suggesting that upregulation of
pyruvate decarboxylase kinase (PDK)-1, an inhibitor of acetyl-CoA
synthesis, may be responsible for OXPHOS regulation in macro-
phages [9]. Yang et al. found that of HIF-1α transcriptional activity,
an effect reportedly associated with succinate accumulation in M1
macrophages, can promote PDK1 mRNA accumulation in both
BMDM and RAW264.7 cells. However, such a model of PDK-1-
mediated suppression of OXPHOS, although demonstrated in tu-
mors cells, is inconsistent with the known need for substantial
citrate export from the mitochondria during proinﬂammatory
cytokine production. In DC, citrate exported from the mitochon-
dria facilitates production of fatty acids needed for endoplasmic
reticulum expansion and development of the Golgi apparatus re-
quired for cytokine production [5]. Suppression of pyruvate de-
hydrogenase by induced PDK-1 would be expected to deprive the
citrate carrier of glucose-derived cargo and blunt these pro-in-
ﬂammatory functions. Furthermore, our ﬁnding of accelerated
rates of glycolysis in Il10 / M1 macrophages where succinate has
W.A. Baseler et al. / Redox Biology 10 (2016) 12–2322not accumulated argue against a role for a succinate-HIF1a-PDK-1
mechanism in the M1 metabolic polarization. Therefore, although
it is clear that HIF-1α does play a role in glycolytic enhancement,
as appreciated as increased expression of multiple HIF-1α targets
in LPS stimulated BMDM, we propose that the down-regulation of
OXPHOS during commitment is mediated entirely via NO and in-
dependent of Hif1α-driven PDK-1 expression. Consistent with this
model, NO is known to facilitate the stabilization of Hif1α via di-
rect suppression of the proyl-hydroxylases (PHD) [25]. However,
the dependency of LPS-induced, Hif1α-driven transcription on NO
production is unclear and requires further study.
M1 polarization of BMDM leads to profound metabolic changes
including alterations to the glycolytic pathway and TCA cycle. Our
metabolomics data from LPS stimulated BMDM are in general
agreement with the broken TCA cycle hypothesis in which the TCA
cycle is blocked, allowing the build up and cytosolic export of ci-
trate and subsequent itaconic acid production. In addition we also
ﬁnd evidence that the arginosuccinate pathway is elevated, per-
mitting accelerated production of NO. Jha et al. suggests that
suppression of isocitrate dehydrogenase (Idh1), which converts
isocitrate to α-ketoglutarate, is the critical factor for TCA rerouting
in M1 macrophages [26]. Our metabolomics show that citrate ac-
cumulation, albeit somewhat truncated, occurs in cells lacking IL-
10 while these cells also show a substantial reduction in alpha
ketoglutarate. Together these ﬁndings show that the TCA break is
intact in IL10/ M1 macrophages. In fact, we ﬁnd the levels of
TCA intermediates to be even lower in M1 macrophages lacking IL-
10 than in WT cells.
The data we present here suggests that a component of the
anti-inﬂammatory effects of IL-10 may lie with its ability to reg-
ulate the metabolic program of myeloid cells. Previous reports
have suggested that IL-10 can suppress the expression of a gly-
colytic phenotype in DC but our ﬁndings demonstrate an alter-
native mode of action [12]. By suppressing the production of NO,
autologous IL-10 preserves OXPHOS in macrophages. Thus the
cytokine affects both aspects of metabolic programming strongly
favoring a phenotype high in OXPHOS. Our ﬁnding that IL-10
production is itself subject to regulation by glucose availability
during transition to glycolysis demonstrates its role as a rheostat
controlling commitment in macrophages. Disruption of this
rheostat in Il10 null mice results in substantially increased NO
production, increased glycolytic ﬂux, and further suppressed
OXPHOS.
Though multiple studies have identiﬁed IL-10 as a potent reg-
ulator of NO production, the mechanisms behind this phenom-
enon remain unclear. Some reports suggest that IL-10 acts at the
transcriptional level via inhibition of Nos2 expression whereas
others show enhanced degradation of NO [27,28]. Alternatively, IL-
10 is reported to block iNOS accumulation without affecting Nos2
mRNA, to induce competing arginase activity, or to suppress LPS-
mediated up regulation of the type-2 cationic amino acid trans-
porter (CAT2) that facilitates arginine uptake [29]. Our data sug-
gest that regardless of its mode of action, the repression of NO and
the associated maintenance of oxidative respiration by IL-10 pro-
motes the highly oxidative program.
In summary, we have shown that acute LPS stimulation of
macrophages leads to an immediate enhancement of glycolysis
followed by long term repression of mitochondrial OXPHOS. Fur-
ther, we have found that this mechanism of glycolytic commit-
ment is NO and IL-10 dependent. Speciﬁcally, we propose that IL-
10 acts as a metabolic rheostat capable of ﬁne-tuning the glyco-
lytic commitment. This is evident during macrophage stimulation
and occurs via regulation of NO production, which exerts pro-
nounced effects at a variety of points within cellular metabolism.
Through continued efforts aimed at elucidating mechanisms, such
as this, that balance between pathogenicity, immunity andmetabolism, we hope to unearth attractive new metabolic targets
that can aid in the regulation of inﬂammatory response.Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.redox.2016.09.005.References
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